Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gene Therapy(FT-003) for Wet AMD
Sponsor: Frontera Therapeutics
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.
Official title: A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2023-08-15
Completion Date
2028-10-15
Last Updated
2024-07-09
Healthy Volunteers
No
Interventions
FT-003
Administered via intraocular injection.
Locations (1)
Tianjin Medical University Eye Hospital
Tianjin, Tianjin,China, China